Compare Jabil Inc (JBL) vs Novartis AG (NVS) Price & Performance

Jabil IncTrade

Novartis AGTrade

Price performance (Past 24H)

Key statistics

Jabil Inc vs Novartis AG — how do they compare? Jabil Inc trades at $319.29 (market cap $32.06B), while Novartis AG trades at $149.81 (market cap $290.25B). The key difference: Novartis AG is far larger — about 9.1× Jabil Inc's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.

	JBL	NVS
Market Cap	$32.06B	$290.25B
Sector	Technology	Health
52-Week High	$385.50	$168.62
52-Week Low	$192.49	$113.50
Enterprise Value	$34.59B	$330.27B
Dividend Yield	0.1%	3.17%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Jabil Inc

JBL trades at $305.91, up 1.63% today but down significantly from recent highs, with technical indicators showing bearish momentum despite oversold RSI readings. The company demonstrates strong fundamental performance with consistent earnings beats, 20.62% ROE, and robust revenue growth projections to $33.6B for 2026. Recent developments include expansion of AI infrastructure capabilities and new logistics facilities.

JBL presents a compelling growth story driven by AI infrastructure demand, with analysts maintaining strong buy ratings and a $448.29 consensus target representing 46% upside. However, elevated P/E ratio of 37.67 and competitive pressures in electronics manufacturing warrant caution. The stock's recent pullback may offer entry opportunity for long-term investors bullish on AI-driven growth.

Novartis AG

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

JBL

View details →

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 22 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

About Jabil Inc

Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.